Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정연 | - |
dc.date.accessioned | 2021-07-19T01:19:36Z | - |
dc.date.available | 2021-07-19T01:19:36Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.citation | CELLULAR AND MOLECULAR LIFE SCIENCES, v. 78, no. 1, page. 207-225 | en_US |
dc.identifier.issn | 1420-682X | - |
dc.identifier.issn | 1420-9071 | - |
dc.identifier.uri | https://link.springer.com/article/10.1007/s00018-020-03490-2 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/162790 | - |
dc.description.abstract | NAD(P)-dependent steroid dehydrogenase-like (NSDHL), an essential enzyme in human cholesterol synthesis and a regulator of epidermal growth factor receptor (EGFR) trafficking pathways, has attracted interest as a therapeutic target due to its crucial relevance to cholesterol-related diseases and carcinomas. However, the development of pharmacological agents for targeting NSDHL has been hindered by the absence of the atomic details of NSDHL. In this study, we reported two X-ray crystal structures of human NSDHL, which revealed a detailed description of the coenzyme-binding site and the unique conformational change upon the binding of a coenzyme. A structure-based virtual screening and biochemical evaluation were performed and identified a novel inhibitor for NSDHL harboring suppressive activity towards EGFR. In EGFR-driven human cancer cells, treatment with the potent NSDHL inhibitor enhanced the antitumor effect of an EGFR kinase inhibitor. Overall, these findings could serve as good platforms for the development of therapeutic agents against NSDHL-related diseases. | en_US |
dc.description.sponsorship | This work was funded by Korea Ministry of Science, Information, Communication, Technology, and Future Planning and the National Research Foundation (NRF) of Korea Grants (NRF-2018R1A2A1A19018526 and NRF-2018R1A5A2024425 to B.-J.L.; NRF-2016R1C1B2014609, NRF-2018R1A6B4023605 and NRF-2019R1H1A1102102 to S.J.L.; and NRF-2017R1C1B2012225 to H.S.K.). This work was also supported by the 2018 BK21 Plus Project for Medicine, Dentistry, and Pharmacy and the National Cancer Center Grant of Korea (NCC-1811040; NCC-1910032; and NCC-1910023). | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER BASEL AG | en_US |
dc.subject | NSDHL | en_US |
dc.subject | Cholesterol synthesis pathway | en_US |
dc.subject | Membrane-anchored protein | en_US |
dc.subject | Structure-based drug design | en_US |
dc.subject | EGFR | en_US |
dc.title | Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1007/s00018-020-03490-2 | - |
dc.relation.page | 1-19 | - |
dc.relation.journal | CELLULAR AND MOLECULAR LIFE SCIENCES | - |
dc.contributor.googleauthor | Kim, Dong‑Gyun | - |
dc.contributor.googleauthor | Cho, Sujin | - |
dc.contributor.googleauthor | Lee, Kyu‑Yeon | - |
dc.contributor.googleauthor | Cheon, Seung‑Ho | - |
dc.contributor.googleauthor | Yoon, Hye‑Jin | - |
dc.contributor.googleauthor | Lee, Joo‑Youn | - |
dc.contributor.googleauthor | Kim, Dongyoon | - |
dc.contributor.googleauthor | Shin, Kwang‑Soo | - |
dc.contributor.googleauthor | Koh, Choong‑Hyun | - |
dc.contributor.googleauthor | Lee, Jeong‑Yeon | - |
dc.relation.code | 2020047090 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | jy2jy2 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.